ACHIEVE-3: Orforglipron Demonstrates Superiority to Semaglutide in Poorly Controlled T2D
Автор: HCPLive
Загружено: 2026-03-05
Просмотров: 38
Описание:
Eli Lilly’s investigational once-daily GLP-1 receptor agonist orforglipron has outperformed oral semaglutide 7 and 14 mg in patients with type 2 diabetes inadequately controlled with metformin. Over 52 weeks, orforglipron resulted in superior improvements in weight and A1C, demonstrating superiority over the primary and all key secondary endpoints. Notably, orforglipron exhibits no food or water restrictions, setting it apart from existing oral GLP-1s.
Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the results of ACHIEVE-3 and the promise of orforglipron as an oral GLP-1 with no dietary restrictions.
Check out the full episode on recent GLP-1 trials and results at https://www.hcplive.com/view/diabetes....
#endocrinology #type2diabetes #glp1
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
